Scholarlink

Background <p>Cardiac fibrosis, a major determinant of heart failure and mortality, results from excessive extracellular matrix deposition following cardiac injury. Despite available pharmacotherapies, clinical outcomes remain unsatisfactory due to adverse effects and limited efficacy. <i>Eclipta alba</i> (L.) Hassk., rich in wedelolactone, a coumarin glycoside with potent antioxidant and anti-inflammatory activity, offers a natural alternative for managing cardiac fibrosis.</p> Objective <p>This study aimed to develop and characterize a liquisolid compact formulation of <i>Eclipta alba</i> extract to enhance solubility, bioavailability, and cardioprotective efficacy, with potential translational application for future clinical studies.</p> Methods <p>A 3² full factorial design optimized the methanolic extraction process based on time and temperature, with phenolic and flavonoid contents serving as response variables. The liquisolid compact was prepared using PEG 400 as a non-volatile solvent and Syloid 244 FP, Syloid XDP 3150 blend as a carrier and coating material to improve dissolution. A cardiac fibrosis model was generated in Wistar rats using the DOCA-salt model, followed by oral administration of <i>Eclipta alba</i> extract (200 and 400&#xa0;mg/kg) and its liquisolid compact (400&#xa0;mg/kg) for 28 days. Hemodynamic, biochemical, and histopathological parameters were evaluated.</p> Results <p>Optimized extraction (24&#xa0;h, 60&#xa0;°C) yielded maximal phenolic (2.35&#xa0;mg/mL) and flavonoid (2.9&#xa0;mg/mL) content. The liquisolid compact achieved 100% in-vitro release within 40&#xa0;min and significantly improved left ventricular function, restored antioxidant enzyme levels, and reduced collagen accumulation.</p> Conclusion <p>The optimized <i>Eclipta alba</i> liquisolid compact demonstrated potent cardioprotective and anti-fibrotic activity in preclinical models, supporting its potential for clinical development as a safe and effective therapeutic for cardiac fibrosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the Cardio-Protective Potential of Eclipta alba Leaves and Its Formulations in Cardiac Fibrosis-Induced Experimental Rats

  • 期刊论文

  • 发表日期：

    2026年3月16日

查看全文
  • Tejal Gandhi,
  • Vaishali Thakkar,
  • Hardik Devadiya,
  • Anjali Patel,
  • Saloni Dalwadi

摘要

Background

Cardiac fibrosis, a major determinant of heart failure and mortality, results from excessive extracellular matrix deposition following cardiac injury. Despite available pharmacotherapies, clinical outcomes remain unsatisfactory due to adverse effects and limited efficacy. Eclipta alba (L.) Hassk., rich in wedelolactone, a coumarin glycoside with potent antioxidant and anti-inflammatory activity, offers a natural alternative for managing cardiac fibrosis.

Objective

This study aimed to develop and characterize a liquisolid compact formulation of Eclipta alba extract to enhance solubility, bioavailability, and cardioprotective efficacy, with potential translational application for future clinical studies.

Methods

A 3² full factorial design optimized the methanolic extraction process based on time and temperature, with phenolic and flavonoid contents serving as response variables. The liquisolid compact was prepared using PEG 400 as a non-volatile solvent and Syloid 244 FP, Syloid XDP 3150 blend as a carrier and coating material to improve dissolution. A cardiac fibrosis model was generated in Wistar rats using the DOCA-salt model, followed by oral administration of Eclipta alba extract (200 and 400 mg/kg) and its liquisolid compact (400 mg/kg) for 28 days. Hemodynamic, biochemical, and histopathological parameters were evaluated.

Results

Optimized extraction (24 h, 60 °C) yielded maximal phenolic (2.35 mg/mL) and flavonoid (2.9 mg/mL) content. The liquisolid compact achieved 100% in-vitro release within 40 min and significantly improved left ventricular function, restored antioxidant enzyme levels, and reduced collagen accumulation.

Conclusion

The optimized Eclipta alba liquisolid compact demonstrated potent cardioprotective and anti-fibrotic activity in preclinical models, supporting its potential for clinical development as a safe and effective therapeutic for cardiac fibrosis.